Brain metabolite alterations and cognitive dysfunction in early Huntington's disease

Movement Disorders

Volumn 27, Issue 7, 2012, Pages 895-902

  Unschuld, Paul G ^a   Edden, Richard A E ^a,b   Carass, Aaron ^a   Liu, Xinyang ^c   Shanahan, Megan ^a   Wang, Xin ^a   Oishi, Kenichi ^a   Brandt, Jason ^a   Bassett, Susan S ^a   Redgrave, Graham W ^a   Margolis, Russell L ^a   van Zijl, Peter C M ^a,b   Barker, Peter B ^a,b   Ross, Christopher A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KENNEDY KRIEGER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Biomarker; Cognition; Glutamate; MRS; NAA; Neurodegeneration

Indexed keywords

4 AMINOBUTYRIC ACID; CHOLINE; CREATINE; CREATINE PHOSPHATE; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; GLYCEROPHOSPHORYLCHOLINE; INOSITOL; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; PHOSPHOETHANOLAMINE; PHOSPHORYLCHOLINE; TAURINE;

ADULT; ARTICLE; BRAIN SIZE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUNTINGTON CHOREA; LINEAR REGRESSION ANALYSIS; MALE; METABOLITE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOMETRY; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ASPARTIC ACID; BRAIN; COGNITION DISORDERS; FEMALE; GLUTAMIC ACID; HUMANS; HUNTINGTON DISEASE; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; REGRESSION ANALYSIS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84862679900     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25010     Document Type: Article

References (65)

1. Brandt J, Bylsma FW, Gross R, Stine OC, Ranen N, Ross CA. Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology. 1996; 46: 527-531.
2. Lawrence AD, Hodges JR, Rosser AE, et al. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain. 1998; 121: 1329-1341.
3. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology. 2000; 54: 452-458.
4. Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011; 10: 31-42.
5. Stout JC, Paulsen JS, Queller S, et al. Neurocognitive signs in prodromal Huntington disease. Neuropsychology. 2011; 25: 1-14.
6. Paulsen JS. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci Rep. 2011; 11: 474-483.
7. Gusella JF, Wexler NS, Conneally PM, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature. 1983; 306: 234-238.
8. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011; 10: 83-98.
9. Gusella JF, McNeil S, Persichetti F, et al. Huntington's disease. Cold Spring Harb Symp Quant Biol. 1996; 61: 615-626.
10. Gasser T, Bressman S, Durr A, Higgins J, Klockgether T, Myers RH. State of the art review: molecular diagnosis of inherited movement disorders. Movement Disorders Society task force on molecular diagnosis. Mov Disord. 2003; 18: 3-18.
11. Aylward EH. Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease. Brain Res Bull. 2007; 72: 152-158.
12. Aylward EH, Nopoulos PC, Ross CA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry. 2011; 82: 405-410.
13. Paulsen JS, Magnotta VA, Mikos AE, et al. Brain structure in preclinical Huntington's disease. Biol Psychiatry. 2006; 59: 57-63.
14. Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology. 2005; 65: 745-747.
15. Rosas HD, Salat DH, Lee SY, et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain. 2008; 131: 1057-1068.
16. Hobbs NZ, Pedrick AV, Say MJ, et al. The structural involvement of the cingulate cortex in premanifest and early Huntington's disease. Mov Disord. 2011; 26: 1684-1690.
17. Jenkins BG, Klivenyi P, Kustermann E, et al. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J Neurochem. 2000; 74: 2108-2119.
18. Bender A, Auer DP, Merl T, et al. Creatine supplementation lowers brain glutamate levels in Huntington's disease. J Neurol. 2005; 252: 36-41.
19. Jenkins BG, Rosas HD, Chen YC, et al. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology. 1998; 50: 1357-1365.
20. Reynolds NC Jr, Prost RW, Mark LP. Heterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington's disease. Brain Res. 2005; 1031: 82-89.
21. Sanchez-Pernaute R, Garcia-Segura JM, del Barrio Alba A, Viano J, de Yebenes JG. Clinical correlation of striatal 1H MRS changes in Huntington's disease. Neurology. 1999; 53: 806-812.
22. Taylor-Robinson SD, Weeks RA, Bryant DJ, et al. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov Disord. 1996; 11: 167-173.
23. van Oostrom JC, Sijens PE, Roos RA, Leenders KL. 1H magnetic resonance spectroscopy in preclinical Huntington disease. Brain Res. 2007; 1168: 67-71.
24. Sturrock A, Laule C, Decolongon J, et al. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology. 2010; 75: 1702-1710.
25. van den Bogaard SJ, Dumas EM, Teeuwisse WM, et al. Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington's disease provides in vivo evidence for impaired energy metabolism. J Neurol. 2011; 258: 2230-2239.
26. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009; 8: 791-801.
27. Hersch SM, Rosas HD. Biomarkers to enable the development of neuroprotective therapies for Huntington's disease. In: Lo DC, Hughes, RE, eds. Neurobiology of Huntington's Disease. Boca Raton, FL: CRC Press; 2011.
28. Weir DW, Sturrock A, Leavitt BR. Development of biomarkers for Huntington's disease. Lancet Neurol. 2011; 10: 573-590.
29. Brandt J, Inscore AB, Ward J, et al. Neuropsychological deficits in Huntington's disease gene carriers and correlates of early "conversion." J Neuropsychiatry Clin Neurosci. 2008; 20: 466-472.
30. Tkac I, Oz G, Adriany G, Ugurbil K, Gruetter R. In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T. Magn Reson Med. 2009; 62: 868-879.
31. Choo IH, Lee DY, Oh JS, et al. Posterior cingulate cortex atrophy and regional cingulum disruption in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2010; 31: 772-779.
32. Kantarci K, Jack CR Jr, Xu YC, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology. 2000; 55: 210-217.
33. Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009; 73: 1193-1199.
34. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997; 42: 85-94.
35. Valenstein E, Bowers D, Verfaellie M, Heilman KM, Day A, Watson RT. Retrosplenial amnesia. Brain. 1987; 110: 1631-1646.
36. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet. 2004; 65: 267-277.
37. Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol. 1997; 41( 5): 689-692.
38. Folstein SE, Jensen B, Leigh RJ, Folstein MF. The measurement of abnormal movement: methods developed for Huntington's disease. Neurobehav Toxicol Teratol. 1983; 5: 605-609.
39. World Medical Association. Declaration of Helsinki. Law Med Health Care. 1991; 19: 264-265.
40. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4: 561-571.
41. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23: 56-62.
42. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189-198.
43. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53: 695-699.
44. Bright P, Jaldow E, Kopelman MD. The National Adult Reading Test as a measure of premorbid intelligence: a comparison with estimates derived from demographic variables. J Int Neuropsychol Soc. 2002; 8: 847-854.
45. Barker PB, Hearshen DO, Boska MD. Single-voxel proton MRS of the human brain at 1.5T and 3.0T. Magn Reson Med. 2001; 45: 765-769.
46. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hanicke W, Sauter R. Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magn Reson Med. 1989; 9: 79-93.
47. Bazin PL, Pham DL. Topology-preserving tissue classification of magnetic resonance brain images. IEEE Trans Med Imaging. 2007; 26: 487-496.
48. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993; 30: 672-679.
49. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed. 2001; 14: 260-264.
50. Hirono N, Mori E, Ishii K, et al. Hypofunction in the posterior cingulate gyrus correlates with disorientation for time and place in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1998; 64: 552-554.
51. Nielsen FA, Balslev D, Hansen LK. Mining the posterior cingulate: segregation between memory and pain components. Neuroimage. 2005; 27( 3): 520-532.
52. Zhou Y, Dougherty JH Jr, Hubner KF, Bai B, Cannon RL, Hutson RK. Abnormal connectivity in the posterior cingulate and hippocampus in early Alzheimer's disease and mild cognitive impairment. Alzheimers Dement. 2008; 4: 265-270.
53. Leech R, Kamourieh S, Beckmann CF, Sharp DJ. Fractionating the default mode network: distinct contributions of the ventral and dorsal posterior cingulate cortex to cognitive control. J Neurosci. 2011; 31: 3217-3224.
54. Brandt J, Shpritz B, Codori AM, Margolis R, Rosenblatt A. Neuropsychological manifestations of the genetic mutation for Huntington's disease in presymptomatic individuals. J Int Neuropsychol Soc. 2002; 8: 918-924.
55. Lawrence AD, Sahakian BJ, Hodges JR, Rosser AE, Lange KW, Robbins TW. Executive and mnemonic functions in early Huntington's disease. Brain. 1996; 119: 1633-1645.
56. Aylward EH, Brandt J, Codori AM, Mangus RS, Barta PE, Harris GJ. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology. 1994; 44: 823-828.
57. Aylward EH, Anderson NB, Bylsma FW, et al. Frontal lobe volume in patients with Huntington's disease. Neurology. 1998; 50: 252-258.
58. Taylor-Robinson SD, Weeks RA, Sargentoni J, et al. Evidence for glutamate excitotoxicity in Huntington's disease with proton magnetic resonance spectroscopy. Lancet. 1994; 343: 1170.
59. Estrada Sanchez AM, Mejia-Toiber J, Massieu L. Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch Med Res. 2008; 39: 265-276.
60. Roze E, Saudou F, Caboche J. Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr Opin Neurol. 2008; 21: 497-503.
61. Walker FO. Huntington's disease. Lancet. 2007; 369: 218-228.
62. Vogt BA, Finch DM, Olson CR. Functional heterogeneity in cingulate cortex: the anterior executive and posterior evaluative regions. Cereb Cortex. 1992; 2: 435-443.
63. Vogt BA, Vogt L, Laureys S. Cytology and functionally correlated circuits of human posterior cingulate areas. Neuroimage. 2006; 29: 452-466.
64. Camicioli RM, Korzan JR, Foster SL, et al. Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. Neurosci Lett. 2004; 354: 177-180.
65. Bustillo JR, Chen H, Gasparovic C, et al. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry. 2011; 69: 19-27.